<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kalvista Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc</link>
<description>Latest news and press releases for Kalvista Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kalvista-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358da478dffbe2df100e1c.webp</url>
<title>Kalvista Pharmaceuticals Inc</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc</link>
</image>
<item>
<title>KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in</description>
</item>
<item>
<title>KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-positive-interim-phase-3-data-from-konfident-kid-trial-of-ekterlyr-sebetralstat-for-children-aged-2-11-years-at-the-2026-global-angioedema-leadership-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-positive-interim-phase-3-data-from-konfident-kid-trial-of-ekterlyr-sebetralstat-for-children-aged-2-11-years-at-the-2026-global-angioedema-leadership-conference</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability</description>
</item>
<item>
<title>KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-reports-eight-months-fiscal-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-reports-eight-months-fiscal-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-present-new-ekterlyr-sebetralstat-data-at-the-2026-global-angioedema-leadership-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-present-new-ekterlyr-sebetralstat-data-at-the-2026-global-angioedema-leadership-conference</guid>
<pubDate>Fri, 20 Mar 2026 11:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England, March 20, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership Conference taking place in Madrid, Spain from March 26–29, 2026.</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday,</description>
</item>
<item>
<title>KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-presents-new-data-highlighting-high-patient-satisfaction-and-evolving-treatment-trends-with-ekterlyr-sebetralstat</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-presents-new-data-highlighting-high-patient-satisfaction-and-evolving-treatment-trends-with-ekterlyr-sebetralstat</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in</description>
</item>
<item>
<title>KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-inclusion-of-ekterlyr-sebetralstat-as-a-first-line-therapy-for-adolescents-12-and-older-in-international-pediatric-hae-guideline</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-inclusion-of-ekterlyr-sebetralstat-as-a-first-line-therapy-for-adolescents-12-and-older-in-international-pediatric-hae-guideline</guid>
<pubDate>Wed, 18 Feb 2026 12:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England, February 18, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-ekterly-sebetralstat-120000411</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-ekterly-sebetralstat-120000411</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England, February 12, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026.</description>
</item>
<item>
<title>KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of</description>
</item>
<item>
<title>KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-provides-update-strong-ekterlyr-launch-preliminary-fourth</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-provides-update-strong-ekterlyr-launch-preliminary-fourth</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025,</description>
</item>
<item>
<title>KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-approval-ekterlyr-sebetralstat-japan-first-and</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-approval-ekterlyr-sebetralstat-japan-first-and</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor</description>
</item>
<item>
<title>KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-provides-operational-update-and-reports-third-quarter</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-provides-operational-update-and-reports-third-quarter</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through</description>
</item>
<item>
<title>KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-presents-new-data-highlighting-patient-satisfaction-ekterlyr</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-presents-new-data-highlighting-patient-satisfaction-ekterlyr</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-upcoming-investor-conferences-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-upcoming-investor-conferences-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-host-third-quarter-financial-results-conference-call-and</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-host-third-quarter-financial-results-conference-call-and</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday,</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-new-ekterlyr-sebetralstat-data-american-college</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-new-ekterlyr-sebetralstat-data-american-college</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for</description>
</item>
<item>
<title>KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-presents-new-data-highlighting-potential-ekterlyr</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-presents-new-data-highlighting-potential-ekterlyr</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked</description>
</item>
<item>
<title>KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-appoints-bilal-arif-chief-operating-officer-and-linea-aspesi</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-appoints-bilal-arif-chief-operating-officer-and-linea-aspesi</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as</description>
</item>
<item>
<title>KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-appointment-bethany-l-sensenig-board-directors</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-announces-appointment-bethany-l-sensenig-board-directors</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L.</description>
</item>
<item>
<title>KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress</title>
<link>https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-new-ekterlyr-sebetralstat-data-20th-german-allergy</link>
<guid isPermaLink="true">https://6ix.com/company/kalvista-pharmaceuticals-inc/news/kalvista-pharmaceuticals-present-new-ekterlyr-sebetralstat-data-20th-german-allergy</guid>
<pubDate>Fri, 26 Sep 2025 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for</description>
</item>
</channel>
</rss>